Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution.

Yoshimoto K, Hatae R, Sangatsuda Y, Suzuki SO, Hata N, Akagi Y, Kuga D, Hideki M, Yamashita K, Togao O, Hiwatashi A, Iwaki T, Mizoguchi M, Iihara K.

Brain Tumor Pathol. 2017 Jul;34(3):103-112. doi: 10.1007/s10014-017-0287-7. Epub 2017 Apr 26.

PMID:
28447171
2.

Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours.

Haque F, Varlet P, Puntonet J, Storer L, Bountali A, Rahman R, Grill J, Carcaboso AM, Jones C, Layfield R, Grundy RG.

Acta Neuropathol Commun. 2017 Jun 6;5(1):45. doi: 10.1186/s40478-017-0449-1.

3.

Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.

Schreck KC, Ranjan S, Skorupan N, Bettegowda C, Eberhart CG, Ames HM, Holdhoff M.

J Neurooncol. 2019 May;143(1):87-93. doi: 10.1007/s11060-019-03134-x. Epub 2019 Mar 12.

4.

Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.

Venneti S, Garimella MT, Sullivan LM, Martinez D, Huse JT, Heguy A, Santi M, Thompson CB, Judkins AR.

Brain Pathol. 2013 Sep;23(5):558-64. doi: 10.1111/bpa.12042. Epub 2013 Mar 6.

5.

H3F3A K27M mutations in thalamic gliomas from young adult patients.

Aihara K, Mukasa A, Gotoh K, Saito K, Nagae G, Tsuji S, Tatsuno K, Yamamoto S, Takayanagi S, Narita Y, Shibui S, Aburatani H, Saito N.

Neuro Oncol. 2014 Jan;16(1):140-6. doi: 10.1093/neuonc/not144. Epub 2013 Nov 26.

6.

Histone H3 K27M mutations in adult cerebellar high-grade gliomas.

Nakata S, Nobusawa S, Yamazaki T, Osawa T, Horiguchi K, Hashiba Y, Yaoita H, Matsumura N, Ikota H, Hirato J, Yoshimoto Y, Yokoo H.

Brain Tumor Pathol. 2017 Jul;34(3):113-119. doi: 10.1007/s10014-017-0288-6. Epub 2017 May 25.

PMID:
28547652
7.

Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.

Fontebasso AM, Schwartzentruber J, Khuong-Quang DA, Liu XY, Sturm D, Korshunov A, Jones DT, Witt H, Kool M, Albrecht S, Fleming A, Hadjadj D, Busche S, Lepage P, Montpetit A, Staffa A, Gerges N, Zakrzewska M, Zakrzewski K, Liberski PP, Hauser P, Garami M, Klekner A, Bognar L, Zadeh G, Faury D, Pfister SM, Jabado N, Majewski J.

Acta Neuropathol. 2013 May;125(5):659-69. doi: 10.1007/s00401-013-1095-8. Epub 2013 Feb 16.

8.

Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.

Castel D, Philippe C, Kergrohen T, Sill M, Merlevede J, Barret E, Puget S, Sainte-Rose C, Kramm CM, Jones C, Varlet P, Pfister SM, Grill J, Jones DTW, Debily MA.

Acta Neuropathol Commun. 2018 Nov 5;6(1):117. doi: 10.1186/s40478-018-0614-1.

9.

Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET.

Vettermann FJ, Felsberg J, Reifenberger G, Hasselblatt M, Forbrig R, Berding G, la Fougère C, Galldiks N, Schittenhelm J, Weis J, Albert NL, Schüller U.

Clin Nucl Med. 2018 Dec;43(12):895-898. doi: 10.1097/RLU.0000000000002300.

PMID:
30358620
10.

H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas.

Gielen GH, Gessi M, Hammes J, Kramm CM, Waha A, Pietsch T.

Am J Clin Pathol. 2013 Mar;139(3):345-9. doi: 10.1309/AJCPABOHBC33FVMO.

PMID:
23429371
11.

High frequency of H3 K27M mutations in adult midline gliomas.

Ebrahimi A, Skardelly M, Schuhmann MU, Ebinger M, Reuss D, Neumann M, Tabatabai G, Kohlhof-Meinecke P, Schittenhelm J.

J Cancer Res Clin Oncol. 2019 Apr;145(4):839-850. doi: 10.1007/s00432-018-02836-5. Epub 2019 Jan 4.

PMID:
30610375
12.

The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children.

Lee J, Solomon DA, Tihan T.

J Neurooncol. 2017 Mar;132(1):1-11. doi: 10.1007/s11060-016-2349-9. Epub 2017 Jan 7. Review. Erratum in: J Neurooncol. 2017 Mar;132(1):13.

13.

H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?

Gessi M, Gielen GH, Hammes J, Dörner E, Mühlen AZ, Waha A, Pietsch T.

J Neurooncol. 2013 Mar;112(1):67-72. doi: 10.1007/s11060-012-1040-z. Epub 2013 Jan 26.

PMID:
23354654
14.

Detecting the H3F3A mutant allele found in high-grade pediatric glioma by real-time PCR.

Zhang R, Han J, Daniels D, Huang H, Zhang Z.

J Neurooncol. 2016 Jan;126(1):27-36. doi: 10.1007/s11060-015-1936-5. Epub 2015 Sep 16.

15.

Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.

Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, Perry A.

Brain Pathol. 2016 Sep;26(5):569-80. doi: 10.1111/bpa.12336. Epub 2015 Dec 14.

16.

Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM.

Pathak P, Jha P, Purkait S, Sharma V, Suri V, Sharma MC, Faruq M, Suri A, Sarkar C.

J Neurooncol. 2015 Feb;121(3):489-97. doi: 10.1007/s11060-014-1675-z. Epub 2014 Dec 6.

PMID:
25479829
17.

A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas.

Venneti S, Santi M, Felicella MM, Yarilin D, Phillips JJ, Sullivan LM, Martinez D, Perry A, Lewis PW, Thompson CB, Judkins AR.

Acta Neuropathol. 2014 Nov;128(5):743-53. doi: 10.1007/s00401-014-1338-3. Epub 2014 Sep 9.

18.

Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation.

Aboian MS, Solomon DA, Felton E, Mabray MC, Villanueva-Meyer JE, Mueller S, Cha S.

AJNR Am J Neuroradiol. 2017 Apr;38(4):795-800. doi: 10.3174/ajnr.A5076. Epub 2017 Feb 9.

19.

Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.

Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M, Bison B, Claviez A, van Vuurden DG, von Bueren AO, Gessi M, Kühnle I, Hans VH, Benesch M, Sturm D, Kortmann RD, Waha A, Pietsch T, Kramm CM.

Neuro Oncol. 2018 Jan 10;20(1):123-131. doi: 10.1093/neuonc/nox149.

20.

Cerebellar high-grade gliomas do not present the same molecular alterations as supratentorial high-grade gliomas and may show histone H3 gene mutations.

Tauziède-Espariat A, Saffroy R, Pagès M, Pallud J, Legrand L, Besnard A, Lacombe J, Lot G, Borha A, Tazi S, Adle-Biassette H, Polivka M, Lechapt E, Varlet P.

Clin Neuropathol. 2018 Sep/Oct;37(5):209-216. doi: 10.5414/NP301104.

PMID:
29809131

Supplemental Content

Support Center